Management of VEGFR-Targeted TKI for Thyroid Cancer
Recent advances in the development of multitarget tyrosine kinase inhibitors (MTKIs), which mainly target the vascular endothelial growth factor receptor (VEGFR), have improved prognoses and dramatically changed the treatment strategy for advanced thyroid cancer. However, adverse events related to t...
Guardado en:
Autores principales: | Tomohiro Enokida, Makoto Tahara |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d297a4b93e314faa9394fbab99a5b059 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation
por: Tian Tian, et al.
Publicado: (2021) -
Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice
por: Susan M. O’Brien, et al.
Publicado: (2021) -
HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
por: Gan J, et al.
Publicado: (2021) -
Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
por: Paula Aldaz, et al.
Publicado: (2021) -
Dermoscopic findings of perifollicular pigmentation associated with vandetanib
por: Jade Cury-Martins, et al.
Publicado: (2018)